China's Health Reform Will Nurture New Drugs, And Boost Use Of Old Ones
Executive Summary
In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, executive director-general at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy
You may also be interested in...
China's Essential Drug Prices Less Severe Than Expected; Some Prices See Increases
SHANGHAI - China's National Development and Reform Commission issued Oct. 2 a guideline price for its Essential Drug List, which stipulates price ceilings for 296 drugs on the first part of the list
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials